Achieve Life Sciences, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Achieve Life Sciences, Inc. (ACHV) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $120.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-28.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2024-03-28
- Achieve Life Sciences, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-12-31 was $0.00.
- Achieve Life Sciences, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-09-30 was $0.00.
- Achieve Life Sciences, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-06-30 was $0.00.
- Achieve Life Sciences, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-03-31 was $455.00K.
- Achieve Life Sciences, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $120.00K.
- Achieve Life Sciences, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $455.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2022-12-31 | $120.00K 10-K · filed 2024-03-28 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $0.00 derived: sum of 2 quarters · filed 2021-03-11 | $0.00 derived: sum of 3 quarters · filed 2021-03-11 | $455.00K 10-K · filed 2021-03-11 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $0.00 derived: sum of 2 quarters · filed 2020-11-12 | $455.00K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $455.00K 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $455.00K 10-Q · filed 2020-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |